Medical treatment of Parkinson's disease;Medikamentöse therapie des morbus Parkinson

Therapeutische Umschau

Volumn 64, Issue 1, 2007, Pages 15-20

  Waldvogel, Daniel ^a  

^a Klinik St Anna   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMINE OXIDASE (FLAVIN CONTAINING); ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOPIN; CLOZAPINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; ISPAGULA; LEVODOPA; MACROGOL 3350; OXYBUTYNIN; PERGOLIDE MESILATE; PRAMIPEXOLE; QUETIAPINE; RASAGILINE; ROPINIROLE; SEROTONIN UPTAKE INHIBITOR; TOLTERODINE; UNCLASSIFIED DRUG;

CAREGIVER; CLINICAL FEATURE; DYSKINESIA; HALLUCINATION; HUMAN; NEUROPROTECTION; PARKINSON DISEASE; QUALITY OF LIFE; REVIEW;

ADULT; AGE FACTORS; AGED; ANTIPARKINSON AGENTS; CHOLINERGIC ANTAGONISTS; CONTROLLED CLINICAL TRIALS; DEMENTIA; DEPRESSION; DOPAMINE AGENTS; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; DYSKINESIAS; HALLUCINATIONS; HUMANS; LEVODOPA; MIDDLE AGED; MULTICENTER STUDIES; PAIN; PARKINSON DISEASE; QUALITY OF LIFE; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

EID: 33846834141     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.64.1.15     Document Type: Review

References (43)

1. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69(3): 308-12.
2. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5(3): 235-45.
3. Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med 2005; 353(10): 1021-7.
4. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56(11 Suppl 5): S1-S88.
5. Birkmayer W, Hornykiewicz O. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien Klin Wochenschr 1961; 73: 787-8.
6. Pahwa R, Lyons K, McGuire D, Silverstein P, Zwiebel F, Robischon M, et al. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Mov Disord 1997; 12(5): 677-81.
7. Dupont E, Andersen A, Boas J, Boisen E, Borgmann R, Helgetveit AC, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996; 93(1): 14-20.
8. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998;55(Suppl 1):23-30.
9. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342(20): 1484-91.
10. Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord 2006; 21(3): 343-53.
11. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin Neuropharmacol 2000; 23(1): 34-44.
12. Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: A national multicenter parallel-group randomized study. J Neurol 2006; 253(5): 601-7.
13. Morrish PK. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? Mov Disord 2003; 18(Suppl 7): S63-70.
14. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB, Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004; 63(2): 301-4.
15. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59(12): 1937-43.
16. Chase TN. Levodopa therapy: consequences of the non-physiologic replacement of dopamine. Neurology 1998; 50(5 Suppl 5): S17-25.
17. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol 1989; 46(10): 1052-60.
18. Bloem BR, Hausdorff JM, Visser JE, Giladi N. Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord 2004; 19(8): 871-84.
19. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, et al. Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006.
20. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol 1997; 42(5): 747-55.
21. Kurth MC, Adler CH, Hilaire MS, Singer C, Waters C, LeWitt P, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997; 48(1): 81-7.
22. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365(9463): 947-54.
23. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64(5): 573-6.
24. Nilsson D, Hansson LE, Johansson K, Nystrom C, Paalzow L, Aquilonius SM. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 1998; 97(3): 175-83.
25. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999; 56(11): 1383-6.
26. Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004; 62(3): 381-8.
27. Schrag A. Psychiatric aspects of Parkinson's disease - an update. J Neurol 2004; 251(7): 795-804.
28. Trosch RM, Friedman JH, Lannon MC, Pahwa R, Smith D, Seeberger LC, et al. Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 1998; 13(3): 377-82.
29. Aarsland D, Alves G, Larsen JP. Disorders of motivation, sexual conduct, and sleep in Parkinson's disease. Adv Neurol 2005; 96: 56-64.
30. Molina JA, Sainz-Artiga MJ, Fraile A, Jimenez-Jimenez FJ, Villanueva C, Orti-Pareja M, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 2000; 15(5): 869-72. 31. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68(4): 423-8.
31. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60(3): 387-92.
32. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2(4): 229-37.
33. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356(9247): 2031-6.
34. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351(24): 2509-18.
35. Burn DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 2002; 17(3): 445-54.
36. Kaye J, Gage H, Kimber A, Storey L, Trend P. Excess burden of constipation in Parkinson's disease: A pilot study. Mov Disord 2006.
37. Eichhorn TE, Oertel WH. Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord 2001; 16(6): 1176-7.
38. Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006; 21(6): 737-45.
39. Swinn L, Schrag A, Viswanathan R, Bloem BR, Lees A, Quinn N. Sweating dysfunction in Parkinson's disease. Mov Disord 2003; 18(12): 1459-63.
40. Moore O, Gurevich T, Korczyn AD, Anca M, Shabtai H, Giladi N. Quality of sexual life in Parkinson's disease. Parkinsonism Relat Disord 2002; 8(4): 243-6.
41. Brown RG, Jahanshahi M, Quinn N, Marsden CD. Sexual function in patients with Parkinson's disease and their partners. J Neurol Neurosurg Psychiatry 1990; 53(6): 480-6.
42. Raffaele R, Vecchio I, Giammusso B, Morgia G, Brunetto MB, Rampello L. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur Urol 2002; 41(4): 382-6.
43. Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC. Pain in Parkinson's disease. Mov Disord 1986; 1(1): 45-9.